NASDAQ:ONCO Onconetix (ONCO) Stock Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free ONCO Stock Alerts $0.12 0.00 (0.00%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$0.11▼$0.1250-Day Range$0.12▼$0.2052-Week Range$0.10▼$1.58Volume213,520 shsAverage Volume527,969 shsMarket Capitalization$2.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Onconetix alerts: Email Address Ad Porter & CompanyThe biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…For the full story, click here. About Onconetix Stock (NASDAQ:ONCO)Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.Read More ONCO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONCO Stock News HeadlinesApril 29, 2024 | finanznachrichten.deImmunovia AB: Immunovia Publishes Interim Report for January-March 2024April 29, 2024 | finance.yahoo.comImmunovia Publishes Interim Report for January-March 2024May 2, 2024 | Chaikin Analytics (Ad)A.I. is a Tidal Wave - Here’s What to BuyThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.April 28, 2024 | finance.yahoo.comOnconetix, Inc. (ONCO) Latest Press Releases & Corporate News - Yahoo FinanceApril 17, 2024 | finance.yahoo.comOnconetix, Inc. (ONCO)April 15, 2024 | finance.yahoo.comBlue Water Vaccines Inc (J4T.SG)March 25, 2024 | bizjournals.comWorkhorse Group clings to Nasdaq listing, plans reverse split amid prolonged stock slumpFebruary 21, 2024 | sg.finance.yahoo.comImmunovia Publishes Full Year Report for 2023May 2, 2024 | Chaikin Analytics (Ad)A.I. is a Tidal Wave - Here’s What to BuyThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.February 21, 2024 | finanznachrichten.deImmunovia AB: Immunovia Publishes Full Year Report for 2023February 14, 2024 | finanznachrichten.deOnconetix, Inc.: Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of DirectorsFebruary 13, 2024 | finance.yahoo.comOnconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of DirectorsFebruary 8, 2024 | benzinga.comOnconetix Stock (NASDAQ:ONCO) Dividends: History, Yield and DatesJanuary 17, 2024 | bizjournals.comOnconetix CEO Neil Campbell resigns 3 months after taking company's lead role; interim namedJanuary 6, 2024 | morningstar.comOnconetix Inc ONCOJanuary 2, 2024 | bizjournals.comBlue Water reinvents itself once more: Biotech firm pivots with $75M acquisition, name changeDecember 30, 2023 | msn.comIT Returns 2024: New Income Tax rules introduced in 2023 that would affect you in 2024December 29, 2023 | msn.comColorado Republican sues to block earned income tax credit increaseDecember 29, 2023 | msn.comNew 2024 laws to impact healthcare, income tax ratesDecember 29, 2023 | news.yahoo.comCut income tax not IHT to revive Tory fortunes, Lamont tells SunakDecember 29, 2023 | news.yahoo.comAnticipated changes in federal income tax brackets and deductionsDecember 29, 2023 | news.yahoo.comTories urge Sunak to focus on slashing income taxDecember 29, 2023 | msn.comIncome tax returns 2024: Top 5 points to note while selecting New Tax Regime for FY2024-25December 29, 2023 | msn.comIncome Tax 2024: Old Tax Regime slabs vs New Tax Regime slabs explained for senior citizensDecember 29, 2023 | detroitnews.comHall: Michigan should reverse income tax hike in new yearDecember 29, 2023 | msn.comIowans get an income tax break in 2024See More Headlines Receive ONCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconetix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/01/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ONCO Previous SymbolNASDAQ:ONCO CUSIPN/A CIK1782107 Webwww.bwbioinc.com Phone513-620-4101FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,410,000.00 Net MarginsN/A Pretax Margin-64,007.53% Return on Equity-331.62% Return on Assets-87.84% Debt Debt-to-Equity Ratio0.08 Current Ratio0.34 Quick Ratio0.32 Sales & Book Value Annual Sales$60,000.00 Price / Sales43.02 Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / Book1.45Miscellaneous Outstanding Shares22,330,000Free Float17,974,000Market Cap$2.58 million OptionableN/A Beta3.38 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Ralph Schiess Ph.D. (Age 45)Interim CEO & Chief Science Officer Mr. Bruce Harmon (Age 66)Chief Financial Officer Dr. Brian Price Ph.D.Head of Technology StrategyMr. Frank A. Jaeger M.A. (Age 54)M.B.A., Senior VP of Marketing & Business Development Mr. Andrew D. Skibo Ph.D.Global Head of Biologics OperationsMr. Theodore Scott YohoHead of Business DevelopmentDr. Ali I. Fattom Ph.D.Head of Science & DiscoveryDr. Jay Newmark M.B.A.M.D., Chief Medical OfficerMr. Christian Bruhlmann (Age 47)Chief Strategy Officer & GM of Europe Dr. Donald L. Very Jr.Ph.D., Senior VP of Commercial Research & DevelopmentMore ExecutivesKey CompetitorsSalarius PharmaceuticalsNASDAQ:SLRXAltamira TherapeuticsNASDAQ:CYTOCohBarNASDAQ:CWBRAllarity TherapeuticsNASDAQ:ALLRClever LeavesNASDAQ:CLVRView All Competitors ONCO Stock Analysis - Frequently Asked Questions How have ONCO shares performed in 2024? Onconetix's stock was trading at $0.1980 at the beginning of 2024. Since then, ONCO shares have decreased by 41.6% and is now trading at $0.1156. View the best growth stocks for 2024 here. Are investors shorting Onconetix? Onconetix saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 527,200 shares, a decrease of 17.1% from the March 15th total of 635,600 shares. Based on an average trading volume of 3,620,000 shares, the short-interest ratio is currently 0.1 days. Approximately 3.2% of the company's shares are short sold. View Onconetix's Short Interest. When is Onconetix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ONCO earnings forecast. How do I buy shares of Onconetix? Shares of ONCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ONCO) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour bank is lying to you.MyBankTrackerForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
